Rethinking Strategies in Pharma Amidst Supply Chain Disruptions
Pharma companies are rethinking strategies due to global supply chain disruptions, focusing on resilience and local grounding.
Cost control is crucial for sustainable competitive advantage, particularly as biopharma faces a patent cliff.
Companies are investing heavily in manufacturing capacity, with a focus on onshoring and cost efficiency.